PT1246638E - Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia - Google Patents
Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemiaInfo
- Publication number
- PT1246638E PT1246638E PT01900978T PT01900978T PT1246638E PT 1246638 E PT1246638 E PT 1246638E PT 01900978 T PT01900978 T PT 01900978T PT 01900978 T PT01900978 T PT 01900978T PT 1246638 E PT1246638 E PT 1246638E
- Authority
- PT
- Portugal
- Prior art keywords
- ipertrigliceridemia
- exendinas
- agonists
- treatment
- exendin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17536500P | 2000-01-10 | 2000-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1246638E true PT1246638E (pt) | 2004-12-31 |
Family
ID=22639978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01900978T PT1246638E (pt) | 2000-01-10 | 2001-01-09 | Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia |
Country Status (12)
Country | Link |
---|---|
US (1) | US20030036504A1 (pt) |
EP (1) | EP1246638B2 (pt) |
JP (1) | JP2003519667A (pt) |
AT (1) | ATE275967T1 (pt) |
AU (1) | AU2006202247A1 (pt) |
CA (1) | CA2396157A1 (pt) |
DE (1) | DE60105547T3 (pt) |
DK (1) | DK1246638T4 (pt) |
ES (1) | ES2227115T5 (pt) |
HK (1) | HK1050477A1 (pt) |
PT (1) | PT1246638E (pt) |
WO (1) | WO2001051078A1 (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2425559T5 (es) * | 1997-01-07 | 2018-02-02 | Amylin Pharmaceuticals, Llc | Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas |
US20030040469A1 (en) * | 2000-03-08 | 2003-02-27 | Knudsen Liselotte Bjerre | Lowering serum lipids |
ATE309818T1 (de) * | 2000-03-08 | 2005-12-15 | Novo Nordisk As | Senkung des serum cholesterols |
ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
BR0212985A (pt) | 2001-09-24 | 2005-08-30 | Imp College Innovations Ltd | Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso |
JP4733922B2 (ja) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | 摂食行動の修正 |
EP2335716A3 (en) | 2004-02-11 | 2011-10-19 | Amylin Pharmaceuticals Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
DE102004043153B4 (de) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
AU2006213607A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US20060190425A1 (en) * | 2005-02-24 | 2006-08-24 | Yuan-Chi Chang | Method for merging multiple ranked lists with bounded memory |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
CN101193626A (zh) * | 2005-03-11 | 2008-06-04 | 益德威士医药股份有限公司 | 奥曲肽的受控释放制剂 |
CN101258163B (zh) | 2005-06-30 | 2013-08-21 | 益普生制药股份有限公司 | Glp-1药物组合物 |
AU2006279680B2 (en) * | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
KR101399178B1 (ko) * | 2005-08-11 | 2014-06-18 | 아스트라제네카 파마수티컬스 엘피 | 선별가능한 특성을 갖는 하이브리드 폴리펩티드 |
SI1971362T1 (sl) | 2005-08-19 | 2015-03-31 | Amylin Pharmaceuticals, Llc | Eksendin za zdravljenje diabetesa in zmanjšanje telesne mase |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
CA2698822A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Minigastrin as a therapeutic agent |
KR20100058550A (ko) * | 2007-09-11 | 2010-06-03 | 몬도바이오테크 래보래토리즈 아게 | 녹농균 감염 치료시 치료제로서의 밴드 3 단백질 (824-829) 및/또는 멜라닌세포-자극 호르몬 방출-저해 인자의 용도 |
US20110263496A1 (en) | 2008-05-21 | 2011-10-27 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholesterol and triglycerides |
WO2009158412A2 (en) * | 2008-06-25 | 2009-12-30 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
CN102231976B (zh) * | 2008-06-25 | 2014-05-07 | Endo药物方法有限公司 | 具有脱模剂的奥曲肽植入物 |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
WO2010138671A1 (en) | 2009-05-28 | 2010-12-02 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
BR112012033295A2 (pt) | 2010-07-02 | 2016-10-11 | Angiochem Inc | polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso |
JP2014504588A (ja) | 2010-12-22 | 2014-02-24 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 膵島細胞移植のためのglp−1受容体アゴニスト |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
PL2934567T3 (pl) | 2012-12-21 | 2018-10-31 | Sanofi | Pochodne eksendyny-4 jako podwójny agonista GLP1/GIP lub potrójny agonista GLP1/GIP/glukagon |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
JP6948330B2 (ja) | 2015-12-23 | 2021-10-13 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対する結合タンパク質をglp−1アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法 |
WO2018071528A1 (en) * | 2016-10-11 | 2018-04-19 | University Of Georgia Research Foundation, Inc. | Proteins and method for treating obesity and associated comorbidities |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
RU2019122785A (ru) * | 2016-12-22 | 2021-01-22 | Санофи | Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
EP3642239A1 (en) | 2017-06-20 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
MX2021010737A (es) | 2019-03-08 | 2021-09-28 | Amgen Inc | Terapia de combinacion por factor de diferenciacion del crecimiento 15. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0930882A2 (en) * | 1996-08-02 | 1999-07-28 | Institut Pasteur De Lille | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
ES2425559T5 (es) * | 1997-01-07 | 2018-02-02 | Amylin Pharmaceuticals, Llc | Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas |
EP1037623A1 (en) * | 1997-12-12 | 2000-09-27 | Warner-Lambert Company | Antihyperlipidemic statin-lp(a) inhibitor combinations |
SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
AU775063C (en) * | 1999-04-30 | 2005-05-12 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
-
2001
- 2001-01-09 DK DK01900978.6T patent/DK1246638T4/da active
- 2001-01-09 JP JP2001551501A patent/JP2003519667A/ja active Pending
- 2001-01-09 WO PCT/US2001/000719 patent/WO2001051078A1/en active IP Right Grant
- 2001-01-09 US US09/756,690 patent/US20030036504A1/en not_active Abandoned
- 2001-01-09 AT AT01900978T patent/ATE275967T1/de active
- 2001-01-09 DE DE60105547.0T patent/DE60105547T3/de not_active Expired - Lifetime
- 2001-01-09 CA CA002396157A patent/CA2396157A1/en not_active Abandoned
- 2001-01-09 PT PT01900978T patent/PT1246638E/pt unknown
- 2001-01-09 ES ES01900978.6T patent/ES2227115T5/es not_active Expired - Lifetime
- 2001-01-09 EP EP01900978.6A patent/EP1246638B2/en not_active Expired - Lifetime
-
2003
- 2003-04-04 HK HK03102440A patent/HK1050477A1/xx not_active IP Right Cessation
-
2006
- 2006-05-26 AU AU2006202247A patent/AU2006202247A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2227115T3 (es) | 2005-04-01 |
EP1246638B2 (en) | 2014-07-30 |
WO2001051078A1 (en) | 2001-07-19 |
ATE275967T1 (de) | 2004-10-15 |
AU784488B2 (en) | 2006-04-13 |
US20030036504A1 (en) | 2003-02-20 |
DE60105547T2 (de) | 2005-10-13 |
HK1050477A1 (en) | 2003-06-27 |
JP2003519667A (ja) | 2003-06-24 |
DE60105547D1 (de) | 2004-10-21 |
CA2396157A1 (en) | 2001-07-19 |
EP1246638A1 (en) | 2002-10-09 |
AU2638001A (en) | 2001-07-24 |
AU2006202247A1 (en) | 2006-06-22 |
ES2227115T5 (es) | 2014-10-30 |
DE60105547T3 (de) | 2014-12-31 |
DK1246638T3 (da) | 2005-01-10 |
EP1246638B1 (en) | 2004-09-15 |
DK1246638T4 (da) | 2014-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1246638E (pt) | Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia | |
CY1107752T1 (el) | Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης | |
Debreceni et al. | The role of homocysteine‐lowering B‐vitamins in the primary prevention of cardiovascular disease | |
AR028512A1 (es) | Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas | |
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
UA82979C2 (ru) | Фармацевтическая композиция, пригодная для перорального введения, которая содержит no-высвобождающие нспвл, лекарственная форма, фармацевтическая комбинация и способы лечения | |
ECSP109852A (es) | Uso de homo y copolímeros para la estabilización de formulaciones de principios activos | |
PA8481401A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino | |
SV2003000886A (es) | Agonistas de ppar ref. pc11023aado/bb | |
ES2196160T3 (es) | Uso de una combinacion de tensioactivos, agentes quelantes y aceites esenciales para desinfeccion efectiva. | |
NO20090185L (no) | Kontrollerte frigjoringsformuleringer | |
UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
AR020345A1 (es) | Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones. | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
MA30768B1 (fr) | Methodes d'administration d'agents hypoglycemiques a longue duree d'action | |
AR071183A1 (es) | Composicion oral que comprende un componente activo y un componente formador de pelicula adhesiva, metodo | |
AR109263A2 (es) | Composición que comprende moxidectina | |
AR074313A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit | |
PT1185253E (pt) | Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac | |
WO2008128191A3 (en) | Oral cephalotaxine dosage forms | |
AR032642A1 (es) | Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral. | |
WO2004052294A3 (en) | Compositions and methods related to lipid:emodin formulations | |
ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
CL2009000986A1 (es) | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma | |
ES2193185T3 (es) | Formulacion farmaceutica para la prevencion o tratamiento previo de una intoxicacion con inhibidores de la colinesterasa organofosforados. |